Nationwide study of eculizumab in paroxysmal nocturnal hemoglobinuria: Evaluation of treatment indications and outcomes
European Journal of Haematology · 2023
DOI: 10.1111/ejh.13946 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Haematology, 2023. Verfasst von Charlotte C M Schaap und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Hemoglobinuria, Paroxysmal. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Alexion Pharmaceuticals.
Abstract (Originalsprache)
Eculizumab is an effective treatment for paroxysmal nocturnal hemoglobinuria (PNH). However, considering the risk of life‐threatening meningococcal disease, life‐long duration and costs, there are strict criteria for initiation of therapy. To evaluate the application and real‐world effectiveness of eculizumab in the Netherlands, a multicenter retrospective cohort study was conducted: indications and treatment outcomes were collected for 105 Dutch PNH patients. In all patients, eculizumab was initiated conforming to indications as formulated in the Dutch PNH guideline. According to recently published response criteria, 23.4% of the patients had reached a complete hematological response, 53.2% a good or partial response, and 23.4% a minor response after 12 months of therapy. In the majority of patients the response remained stable during long‐term follow‐up. The degree and relevance of extravascular hemolysis significantly differed between response groups ( p = 0.002). Improvements of EORTC‐QLQc30 and FACIT‐fatigue scores were observed, however patients reported lower scores than the general population. A detailed evaluation of 18 pregnancies during eculizumab showed no maternal or fetal deaths, and no thromboembolic events during pregnancy. This study demonstrates that the majority of patients benefit from eculizumab when adhering to the indications as formulated in the Dutch PNH guideline. However, novel therapies are needed to further improve real‐world outcomes, such as hematological responses and quality of life.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
- Department of Hematology, Internal Medicine, Maastricht University Medical Centre+, Maastricht, The Netherlands.
- Department of Clinical Hematology, Amsterdam University Medical Centers, Academic Medical Center, Amsterdam, The Netherlands.
- Pediatric Hematology Department, Wilhelmina Children's Hospital, University Medical Centre Utrecht, Utrecht, The Netherlands.
- Department of Obstetrics and Gynecology, Radboud University Medical Center, Nijmegen, The Netherlands.
- Department of Laboratory Medicine-Laboratory for Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.
ORCID-Profile: Charlotte C M Schaap, Floor C J I Heubel-Moenen, Erfan Nur, Marije Bartels, Olivier W H van der Heijden, Emiel de Jonge, Frank W M B Preijers, Nicole M A Blijlevens, Saskia M C Langemeijer
Förderung
- Alexion Pharmaceuticals
Zitieren
APA
Schaap, C. C. M., Heubel-Moenen, F. C. J. I., Nur, E., Bartels, M., van der Heijden, O. W. H., de Jonge, E., Preijers, F. W. M. B., Blijlevens, N. M. A., Langemeijer, S. M. C., & Dutch PNH Working Group (2023). Nationwide study of eculizumab in paroxysmal nocturnal hemoglobinuria: Evaluation of treatment indications and outcomes. European Journal of Haematology. https://doi.org/10.1111/ejh.13946
Vancouver
Schaap CCM, Heubel-Moenen FCJI, Nur E, Bartels M, van der Heijden OWH, de Jonge E, et al. Nationwide study of eculizumab in paroxysmal nocturnal hemoglobinuria: Evaluation of treatment indications and outcomes. European Journal of Haematology. 2023. doi:10.1111/ejh.13946
BibTeX
@article{Schaap2023,
author = {Schaap, Charlotte C M and Heubel-Moenen, Floor C J I and Nur, Erfan and Bartels, Marije and van der Heijden, Olivier W H and de Jonge, Emiel and Preijers, Frank W M B and Blijlevens, Nicole M A and Langemeijer, Saskia M C and Dutch PNH Working Group, Dutch PNH Working Group},
title = {Nationwide study of eculizumab in paroxysmal nocturnal hemoglobinuria: Evaluation of treatment indications and outcomes},
journal = {European Journal of Haematology},
year = {2023},
doi = {10.1111/ejh.13946}
}
EUVIMED